» Articles » PMID: 21715507

Phenotypic and Immunologic Comparison of Clade B Transmitted/founder and Chronic HIV-1 Envelope Glycoproteins

Abstract

Sexual transmission of human immunodeficiency virus type 1 (HIV-1) across mucosal barriers is responsible for the vast majority of new infections. This relatively inefficient process results in the transmission of a single transmitted/founder (T/F) virus, from a diverse viral swarm in the donor, in approximately 80% of cases. Here we compared the biological activities of 24 clade B T/F envelopes (Envs) with those from 17 chronic controls to determine whether the genetic bottleneck that occurs during transmission is linked to a particular Env phenotype. To maximize the likelihood of an intact mucosal barrier in the recipients and to enhance the sensitivity of detecting phenotypic differences, only T/F Envs from individuals infected with a single T/F variant were selected. Using pseudotyping to assess Env function in single-round infectivity assays, we compared coreceptor tropism, CCR5 utilization efficiencies, primary CD4(+) T cell subset tropism, dendritic cell trans-infections, fusion kinetics, and neutralization sensitivities. T/F and chronic Envs were phenotypically equivalent in most assays; however, T/F Envs were modestly more sensitive to CD4 binding site antibodies b12 and VRC01, as well as pooled human HIV Ig. This finding was independently validated with a panel of 14 additional chronic HIV-1 Env controls. Moreover, the enhanced neutralization sensitivity was associated with more efficient binding of b12 and VRC01 to T/F Env trimers. These data suggest that there are subtle but significant structural differences between T/F and chronic clade B Envs that may have implications for HIV-1 transmission and the design of effective vaccines.

Citing Articles

Generation and characterization of infectious molecular clones of transmitted/founder HIV-1 subtype C viruses.

Luthuli B, Gounder K, Deymier M, Dong K, Balazs A, Mann J Virology. 2023; 583:14-26.

PMID: 37084644 PMC: 10208420. DOI: 10.1016/j.virol.2023.04.001.


The apparent interferon resistance of transmitted HIV-1 is possibly a consequence of enhanced replicative fitness.

Sugrue E, Wickenhagen A, Mollentze N, Aziz M, Sreenu V, Truxa S PLoS Pathog. 2022; 18(11):e1010973.

PMID: 36399512 PMC: 9718408. DOI: 10.1371/journal.ppat.1010973.


A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.

Rindler A, Kuster H, Neumann K, Leemann C, Braun D, Metzner K Viruses. 2021; 13(3).

PMID: 33806576 PMC: 8000554. DOI: 10.3390/v13030404.


HIV-1 Envelope Glycosylation and the Signal Peptide.

Lambert G, Upadhyay C Vaccines (Basel). 2021; 9(2).

PMID: 33669676 PMC: 7922494. DOI: 10.3390/vaccines9020176.


HIV-1 Entry and Prospects for Protecting against Infection.

Bruxelle J, Trattnig N, Mureithi M, Landais E, Pantophlet R Microorganisms. 2021; 9(2).

PMID: 33499233 PMC: 7911371. DOI: 10.3390/microorganisms9020228.


References
1.
Burton D, Pyati J, Koduri R, Sharp S, Thornton G, Parren P . Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994; 266(5187):1024-7. DOI: 10.1126/science.7973652. View

2.
Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C . Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol. 2005; 79(13):8454-69. PMC: 1143729. DOI: 10.1128/JVI.79.13.8454-8469.2005. View

3.
Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J . Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol. 2004; 78(4):1718-29. PMC: 369469. DOI: 10.1128/jvi.78.4.1718-1729.2004. View

4.
Piguet V, Steinman R . The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol. 2007; 28(11):503-10. PMC: 7106400. DOI: 10.1016/j.it.2007.07.010. View

5.
Eckstein D, Penn M, Korin Y, Zack J, Kreisberg J, Roederer M . HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity. 2001; 15(4):671-82. DOI: 10.1016/s1074-7613(01)00217-5. View